Fenofibrate is an Effective Tool in Dyslipidaemia
Increased risk of cardiovascular disease in type 2 diabetes is attributable in part to the high prevalence of associated risk factors including hypertension and diabetic dyslipidaemia, the latter characterised by elevated plasma triglyceride levels and low plasma levels of high-density lipoprotein cholesterol (HDL-C). Fibrates are used in patients with dyslipidaemia and high cardiovascular risk, where the greatest benefits of fenofibrate are seen among those with marked hypertriglyceridemia.
Modern Medicine – Issue 5 2021
